In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin

@inproceedings{Santoro2016InvivoET,
  title={In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin},
  author={Matteo Santoro and Walter Maetzler and Petros Stathakos and Heather L. Martin and Markus Hobert and Tim W Rattay and Thomas Gasser and John V. Forrester and D. Berg and Kevin J Tracey and Gernot Riedel and Peter Teismann},
  booktitle={Neurobiology of Disease},
  year={2016}
}
High-mobility group box 1 (HMGB1) is a nuclear and cytosolic protein that is released during tissue damage from immune and non-immune cells - including microglia and neurons. HMGB1 can contribute to progression of numerous chronic inflammatory and autoimmune diseases which is mediated in part by interaction with the receptor for advanced glycation endproducts (RAGE). There is increasing evidence from in vitro studies that HMGB1 may link the two main pathophysiological components of Parkinson's… CONTINUE READING